Evidence map›Paper›PMID 35842643›Full record

ArticleJournal of hematology & oncology2022

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.

Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K Moyo, Nishitha Reddy, Julia Sheets, David M Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa and 35 more

Open access · goldAbstract readLetterMulticenter StudyComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 1 country.

Narendranath EpperlaDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, 43210, USA. Narendranath.Epperla@osumc.edu.
Qiuhong ZhaoDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Sayan Mullick ChowdhuryDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Lauren SheaWashington University, St. Louis, MO, USA.
Tamara K MoyoLevine Cancer Center, Atrium Health, Charlotte, NC, USA.
Nishitha ReddyVanderbilt University Medical Center, Nashville, TN, USA.
Julia SheetsUniversity of North Carolina, Chapel Hill, NC, USA.
David M WeinerPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Praveen Ramakrishnan GeethakumariHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Malathi KandarpaRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Ximena Jordan BrunoUniversity of Vermont, Burlington, VT, USA.
Colin ThomasThomas Jefferson University, Philadelphia, PA, USA.
Michael C ChurnetskiWinship Cancer Institute, Emory University Medical Center, Atlanta, GA, USA.
Andrew HsuBrown University, Providence, RI, USA.
Luke ZurbriggenUniversity of Wisconsin, Madison, WI, USA.
Cherie TanCancer Institute of New Jersey, New Brunswick, NJ, USA.
Kathryn LindseyMedical University of South Carolina, Charleston, SC, USA.
Joseph MaakaronUniversity of Minnesota, Minneapolis, MN, USA.
Paolo F CaimiUniversity Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Pallawi TorkaRoswell Park Cancer Institute, Buffalo, NY, USA.
Celeste BelloH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Sabarish AyyappanUniversity of Iowa, Iowa City, IA, USA.
Reem KarmaliNorthwestern University, Chicago, IL, USA.
Seo-Hyun KimRush University, Chicago, IL, USA.
Anna KressYale University, New Haven, CT, USA.
Shalin KothariYale University, New Haven, CT, USA.
Yazeed SawalhaDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Beth ChristianDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Kevin A DavidCancer Institute of New Jersey, New Brunswick, NJ, USA.
Irl Brian GreenwellMedical University of South Carolina, Charleston, SC, USA.
Murali JanakiramUniversity of Minnesota, Minneapolis, MN, USA.
Vaishalee P KenkreUniversity of Wisconsin, Madison, WI, USA.
Adam J OlszewskiBrown University, Providence, RI, USA.
Jonathon B CohenWinship Cancer Institute, Emory University Medical Center, Atlanta, GA, USA.
Neil PalmisianoThomas Jefferson University, Philadelphia, PA, USA.
Elvira UmyarovaUniversity of Vermont, Burlington, VT, USA.
Ryan A WilcoxRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Farrukh T AwanHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Juan Pablo AlderuccioUniversity of Miami, Miami, FL, USA.
Stefan K BartaPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Natalie S GroverUniversity of North Carolina, Chapel Hill, NC, USA.
Nilanjan GhoshLevine Cancer Center, Atrium Health, Charlotte, NC, USA.
Nancy L BartlettWashington University, St. Louis, MO, USA.
Alex F Herrera *City of Hope, Duarte, CA, USA.
Geoffrey Shouse *City of Hope, Duarte, CA, USA.
The Ohio State University · USBrown University · USCancer Institute of Florida · USCity of Hope · USLevine Cancer Institute · USMedical University of South Carolina · USThe University of Texas Southwestern Medical Center · USThomas Jefferson University · USUniversity of Michigan–Ann Arbor · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · USUniversity of Pennsylvania · USUniversity of Vermont · USUniversity of Wisconsin–Madison · USWashington University in St. Louis · USYale University · USEmory University · USMoffitt Cancer Center · USNorthwestern University · USRoswell Park Comprehensive Cancer Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
NCATS NIH HHS UL1 TR001422NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical practice are largely unknown. To answer this question, we performed a multicenter (25 US centers) cohort study and divided the study population into three groups: "ibrutinib responders"-patients who achieved complete or partial response (CR/PR) to ibrutinib; "stable disease (SD)"; and "primary progressors (PP)"-patients with progression of disease as their best response to ibrutinib. One hundred and nineteen patients met the eligibility criteria with 58%/17% ORR/CR, 29% with SD, and 13% with PP. The median PFS and OS were 29 and 71.4 months, respectively, with no difference in PFS or OS based on the ibrutinib line of therapy or type of therapy before ibrutinib. Patients with complex cytogenetics had an inferior PFS (HR = 3.08, 95% CI 1.23-7.67, p = 0.02), while those with both complex cytogenetics (HR = 3.00, 95% CI 1.03-8.68, p = 0.04) and PP (HR = 13.94, 95% CI 5.17-37.62, p < 0.001) had inferior OS. Only primary refractory disease to first-line therapy predicted a higher probability of PP to ibrutinib (RR = 3.77, 95% CI 1.15-12.33, p = 0.03). In this largest study to date evaluating outcomes of R/R MZL treated with ibrutinib, we show that patients with primary refractory disease and those with PP on ibrutinib are very high-risk subsets and need to be prioritized for experimental therapies.

Indexed as

Lymphoma, B-Cell, Marginal ZoneAdenineCohort StudiesHumansNeoplasm Recurrence, LocalPiperidinesPyrazolesPyrimidinesTreatment OutcomeAdenineibrutinibPiperidinesPyrazolesPyrimidinesIbrutinibMarginal zone lymphomaMZLRefractoryRelapsed

Identifiers

PMID35842643
PMCPMC9287914
OpenAlexW4285588894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.